Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger H G
Department of Surgery, University of Ulm, Germany.
Gastroenterology. 1993 Apr;104(4):1165-70. doi: 10.1016/0016-5085(93)90288-n.
A multicenter controlled study was performed to evaluate the effect of high doses of the low molecular weight protease inhibitor gabexate mesilate on mortality and complications associated with moderate and severe acute pancreatitis.
Two hundred twenty-three patients from 29 hospitals were entered in the randomized, double-blind trial. Admission to the study was based on strict criteria excluding mild acute pancreatitis. The patients received placebo or 4 g gabexate mesilate per day intravenously for 7 days. All patients were followed up for 90 days after randomization. The analysis was based on 14 complications, including death.
There was no statistical difference in either mortality or complications associated with acute pancreatitis between the placebo and gabexate mesilate groups.
The results show that gabexate mesilate was not effective in preventing complications and mortality in acute pancreatitis.
开展了一项多中心对照研究，以评估高剂量低分子量蛋白酶抑制剂甲磺酸加贝酯对中重度急性胰腺炎相关死亡率和并发症的影响。
来自29家医院的223例患者进入了这项随机双盲试验。纳入研究基于严格的标准，排除轻度急性胰腺炎。患者接受安慰剂或每天4克甲磺酸加贝酯静脉注射，共7天。所有患者在随机分组后随访90天。分析基于14种并发症，包括死亡。
安慰剂组和甲磺酸加贝酯组在急性胰腺炎相关的死亡率或并发症方面均无统计学差异。
结果表明，甲磺酸加贝酯在预防急性胰腺炎的并发症和死亡率方面无效。
Zotero 插件